Acutaas Chemicals (ACUTAAS) investor relations material

Executive summary

• Q2 FY27 revenue rose 42.7% YoY to ₹43,691.64 lakh, led by Pharmaceutical Intermediates; Specialty Chemicals were softer.

• FY27 revenue growth guidance increased to ~30%; CDMO revenue targets advanced to ₹1,000 crore in FY27 and ₹2,000 crore by FY30.

• South Korea semiconductor materials facility opened ahead of schedule and was in trial runs at September 30, 2026.

Financial highlights

• Q2 FY27 revenue was ₹43,691.64 lakh, up 42.7% YoY; EBITDA was ₹1,760 million, up 84.6%, and PAT was ₹1,231 million, up 71.4%.

• Q2 gross profit was ₹2,715 million, up 59%; gross margin expanded 637 bps YoY to 62.1%.

• H1 FY27 revenue was ₹76,659.12 lakh, up 49.3%; EBITDA was ₹2,890 million, up 97.7%, and PAT was ₹1,981 million, up 71%.

• Consolidated profit attributable to owners was ₹12,516.92 lakh in Q2 and ₹19,942.93 lakh in H1 FY27, higher YoY in both periods.

Outlook and guidance

• FY27 revenue growth guidance rose from 25% to ~30%; EBITDA margin guidance increased to 38%-40%.

• CDMO revenue target is ₹1,000 crore in FY27, one year ahead of the prior timeline, and ₹2,000 crore by FY30; new contracts are expected to contribute from H2 FY27.

• Eight to ten CDMO products are in the pipeline, with multiple products expected to enter revenue streams over the next 1.5 years; CDMO margins are expected to remain broadly in the current range.

• Battery chemical revenue is expected to ramp over the next two to three quarters; semiconductor chemicals are expected to start contributing from FY28.

• Bulk electronic-grade chemical production is targeted for H1 FY29 after ~1.5 years of project execution.